This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This may be due to inhibition of the MEK-MAPK pathway during DNA damage response, resulting in radiosensitization of cancer cells to 177Lu-rhPSMA-10.1. Results from this preclinical study presented at AACR demonstrated a synergistic therapeutic effect between 177Lu-rhPSMA-10.1 and an MEK inhibitor.
It also acts as a radiosensitizer that can be combined with transarterial radioembolization (TARE) to treat primary and secondary liver tumors. Capecitabine has been proven effective as adjuvant chemotherapy for resectable biliary tract cancer (BTC).
I anticipate that the benefit of radiopharmaceuticals will be maximized by combining radiopharmaceutical therapies with a vast array of other agents including immunotherapies, chemotherapeutics, radiosensitizers and radioprotectors. This is already showing promise with several ongoing trials of approved and developmental radiopharmaceuticals.
Not only are children more radiosensitive than adults (the cancer risk per unit dose of ionizing radiation is higher), but children also have a longer expected lifetime, which puts them at greater risk of cancer following radiation exposure.(1) The balance of dose and image quality is even more important in pediatric medical imaging.
Since children are more radiosensitive and prone to the negative repercussions of radiation than adults, technical factors should be modified to limit radiation to ONLY what’s necessary for diagnosis. These “pieces” are the two epiphyseal plates of the femur. These will fuse later in life and appear more like the adult femur image.
This puts shear stress on the tumor endothelium and activates the production of ceramide, a radiosensitizer. Corinne Wessner from Thomas Jefferson University discusses early study results at UltraCon showing the potential of ultrasound-triggered microbubble destruction in treating liver disease. The average tumor diameter recorded was 4.2
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content